156 related articles for article (PubMed ID: 28060762)
1. Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.
Pott LL; Hagemann S; Reis H; Lorenz K; Bracht T; Herold T; Skryabin BV; Megger DA; Kälsch J; Weber F; Sitek B; Baba HA
Oncotarget; 2017 Feb; 8(7):11950-11962. PubMed ID: 28060762
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma.
Wang N; Feng Y; Tan HY; Cheung F; Hong M; Lao L; Nagamatsu T
J Ethnopharmacol; 2015 Apr; 164():309-18. PubMed ID: 25700642
[TBL] [Abstract][Full Text] [Related]
3. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
4. A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival.
Liu F; Zhu C; Huang X; Cai J; Wang H; Wang X; He S; Liu C; Yang X; Zhang Y; Zhang T
Pathol Res Pract; 2014 Dec; 210(12):885-92. PubMed ID: 25169131
[TBL] [Abstract][Full Text] [Related]
5. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
7. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4α on hepatocellular carcinoma.
Jiang CF; Wen LZ; Yin C; Xu WP; Shi B; Zhang X; Xie WF
Oncotarget; 2016 May; 7(19):27408-21. PubMed ID: 27050273
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
10. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation.
Kaul G; Pattan G; Rafeequi T
Cell Biochem Funct; 2011 Apr; 29(3):227-34. PubMed ID: 21394738
[TBL] [Abstract][Full Text] [Related]
11. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?
Pascale RM; Joseph C; Latte G; Evert M; Feo F; Calvisi DF
DNA Repair (Amst); 2016 Nov; 47():12-20. PubMed ID: 27789167
[TBL] [Abstract][Full Text] [Related]
12. Expression of Raf kinase inhibitor protein in human hepatoma tissues by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight methods.
Tsao DA; Shiau YF; Tseng CS; Chang HR
Indian J Cancer; 2016; 53(2):216-219. PubMed ID: 28071612
[TBL] [Abstract][Full Text] [Related]
13. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
[TBL] [Abstract][Full Text] [Related]
14. Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.
Wang J; Yang T; Chen H; Li H; Zheng S
Biochem Biophys Res Commun; 2018 Apr; 498(3):424-430. PubMed ID: 29477843
[TBL] [Abstract][Full Text] [Related]
15. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
16. BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Breunig C; Mueller BJ; Umansky L; Wahl K; Hoffmann K; Lehner F; Manns MP; Bantel H; Falk CS
Clin Cancer Res; 2014 May; 20(9):2410-23. PubMed ID: 24573550
[TBL] [Abstract][Full Text] [Related]
17. Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways.
Knebel A; Haydon CE; Morrice N; Cohen P
Biochem J; 2002 Oct; 367(Pt 2):525-32. PubMed ID: 12171600
[TBL] [Abstract][Full Text] [Related]
18. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization.
Zhao Y; Wang X; Wang T; Hu X; Hui X; Yan M; Gao Q; Chen T; Li J; Yao M; Wan D; Gu J; Fan J; He X
Hepatology; 2011 Feb; 53(2):493-503. PubMed ID: 21274871
[TBL] [Abstract][Full Text] [Related]
20. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
